Non-small cell lung cancer (NSCLC) is one of the leading causes of cancer mortality. MicroRNAs (miRNAs), small noncoding RNAs, regulate the expression of genes that play roles in human cancer via posttranscriptional inhibition.
Methods
To identify the potential miRNA biomarkers in NSCLC, we downloaded the miRNA expression profile (ID: GSE29248) of NSCLC from the Gene Expression Omnibus (GEO) database and analyzed the differentially expressed miRNAs in NSCLC tissue compared with normal control tissue. Then the targets of these differentially expressed miRNAs were screened and used in network construction and functional enrichment analysis.
Results
We identified a total of 17 miRNAs that showed a significantly differential expression in NSCLC tissue. We found that miR-34b and miR-520h might play important roles in the regulation of NSCLC, miR-22 might be a novel biomarker as an oncogene, and miR-448 might promote, while miR-654-3p prevents, NSCLC progression.
Conclusions
Our study may provide the groundwork for further clinical molecular target therapy experiments in NSCLC.
JemalA., MaJ., RosenbergP.S., SiegelR., AndersonW.F.Increasing lung cancer death rates among young women in southern and midwestern States. J Clin Oncol.2012; 30(22): 2739–2744.
2.
KesanakurtiD., MaddirelaD.R., ChittiveluS., RaoJ.S., ChettyC.Suppression of tumor cell invasiveness and in vivo tumor growth by microRNA-874 in non-small cell lung cancer. Biochem Biophys Res Commun.2013; 434(3): 627–633.
3.
LeeR.C., FeinbaumR.L., AmbrosV.The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell.1993; 75(5): 843–854.
4.
WightmanB., HaI., RuvkunG.Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell.1993; 75(5): 855–862.
5.
BartelD.P.Micro RNAs: genomics, biogenesis, mechanism, and function. Cell.2004; 116(2): 281–297.
6.
FieldJ.K., OudkerkM., PedersenJ.H., DuffyS.W.Prospects for population screening and diagnosis of lung cancer. Lancet.2013; 382(9893): 732–741.
7.
Esquela-KerscherA., TrangP., WigginsJ.F.. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle.2008; 7(6): 759–764.
8.
FontanaL., FioriM.E., AlbiniS.. Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. PLoS ONE.2008; 3(5): e2236.
9.
GarzonR., MarcucciG., CroceC.M.Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov.2010; 9(10): 775–789.
10.
KitadeY., AkaoY.MicroRNAs and their therapeutic potential for human diseases: microRNAs, miR-143 and -145, function as anti-oncomirs and the application of chemically modified miR-143 as an anti-cancer drug. J Pharmacol Sci.2010; 114(3): 276–280.
11.
LiuX., SempereL.F., GalimbertiF.. Uncovering growth-suppressive MicroRNAs in lung cancer. Clin Cancer Res.2009; 15(4): 1177–1183.
MaL., HuangY., ZhuW.. An integrated analysis of miRNA and mRNA expressions in non-small cell lung cancers. PLoS ONE.2011; 6(10): e26502.
14.
IrizarryR.A., HobbsB., CollinF.. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics.2003; 4(2): 249–264.
15.
XiaoF., ZuoZ., CaiG., KangS., GaoX., LiT.miRecords: an integrated resource for microRNA-target interactions. Nucleic Acids Res.2009; 37(Database issue): D105–D110.
WillisR.C., HogueC.W.V.Searching, viewing, and visualizing data in the Biomolecular Interaction Network Database (BIND)[J]. Current protocols in bioinformatics.2006; 8.9.1–8.9.30.
18.
ShannonP., MarkielA., OzierO.. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res.2003; 13(11): 2498–2504.
19.
HulseggeI., KommadathA., SmitsM.A.Globaltest and GOEAST: two different approaches for Gene Ontology analysis. BMC Proc, 3 Suppl 4: S10, 2009.
20.
HuangW., ShermanB.T., LempickiR.A.Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc.2009; 4(1): 44–57.
21.
BenjaminiY., HochbergY.Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc, B.1995; Series B (Methodological): 289–300.
22.
KosakaN., TakeshitaF., YoshiokaY.. Therapeutic Application of MicroRNAs in Cancer[M]//RNA Interference from Biology to Therapeutics. Springer US, 2013: 299–314.
23.
CampayoM., NavarroA., ViñolasN.. A dual role for KRT81: a miR-SNP associated with recurrence in non-small-cell lung cancer and a novel marker of squamous cell lung carcinoma. PLoS ONE.2011; 6(7): e22509.
24.
ToyotaM., SuzukiH., SasakiY.. Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res.2008; 68(11): 4123–4132.
25.
RokhlinO.W., ScheinkerV.S., TaghiyevA.F., BumcrotD., GloverR.A., CohenM.B.MicroRNA-34 mediates AR-dependent p53-in-duced apoptosis in prostate cancer. Cancer Biol Ther.2008; 7(8): 1288–1296.
26.
JiQ., HaoX., MengY.. Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer.2008; 8(1): 266.
27.
MajidS., DarA.A., SainiS.. miRNA-34b inhibits prostate cancer through demethylation, active chromatin modifications, and AKT pathways. Clin Cancer Res.2013; 19(1): 73–84.
28.
LeeY-M, LeeJ-Y, HoC-C. miRNA-34b as a tumor suppressor in estrogen-dependent growth of breast cancer cells. Breast Cancer Res.2011; 13(6): R116
29.
WangF., XueX., WeiJ.. hsa-miR-520h downregulates ABCG2 in pancreatic cancer cells to inhibit migration, invasion, and side populations. Br J Cancer.2010; 103(4): 567–574.
30.
YuY.H., ChenH.A., ChenP.S.. MiR-520h-mediated FOXC2 regulation is critical for inhibition of lung cancer progression by resveratrol. Oncogene.2013; 32(4): 431–443.
31.
ChangY.W., HungM.C., SuJ.L.The anti-tumor activity of E1A and its implications in cancer therapy. Arch Immunol Ther Exp (Warsz).2014; 62(3): 195–204.
32.
WangZ., LiY., BanerjeeS., SarkarF.H.Emerging role of Notch in stem cells and cancer. Cancer Lett.2009; 279(1): 8–12.
33.
LobovI.B., RenardR.A., PapadopoulosN.. Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting. Proc Natl Acad Sci USA.2007; 104(9): 3219–3224.
34.
LillyB., KennardS.Differential gene expression in a coculture model of angiogenesis reveals modulation of select pathways and a role for Notch signaling. Physiol Genomics.2009; 36(2): 69–78.
35.
RoselliM., MineoT.C., BasiliS.. Vascular endothelial growth factor (VEGF-A) plasma levels in non-small cell lung cancer: relationship with coagulation and platelet activation markers. Thrombosis and Haemostasis-Stuttgart-2003; 89: 177–184.
36.
Jantus-LewintreE., SanmartínE., SireraR.. Combined VEGF-A and VEGFR-2 concentrations in plasma: diagnostic and prognostic implications in patients with advanced NSCLC. Lung Cancer.2011; 74(2): 326–331.
37.
LicciulliS., AvilaJ.L., HanlonL.. Notch1 is required for Krasinduced lung adenocarcinoma and controls tumor cell survival via p53. Cancer Res.2013; 73(19): 5974–5984.
38.
SullivanJ.P., SpinolaM., DodgeM.. Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. Cancer Res.2010; 70(23): 9937–9948.
39.
WangL., WangJ.MicroRNA-mediated breast cancer metastasis: from primary site to distant organs. Oncogene.2012; 31(20): 2499–2511.
40.
LiQ.Q., ChenZ.Q., XuJ.D.. Overexpression and involvement of special AT-rich sequence binding protein 1 in multidrug resistance in human breast carcinoma cells. Cancer Sci.2010; 101(1): 80–86.
41.
MaoL., YangC., WangJ.. SATB1 is overexpressed in metastatic prostate cancer and promotes prostate cancer cell growth and invasion. J Transl Med.2013; 11(1): 111.
42.
WangM., YinB., MatsuedaS.. Identification of special AT-rich sequence binding protein 1 as a novel tumor antigen recognized by CD8+ T cells: implication for cancer immunotherapy. PLoS One.2013; 8(2): e56730.
43.
SelingerC.I., CooperW.A., Al-SohailyS.. Loss of special AT-rich binding protein 1 expression is a marker of poor survival in lung cancer. J Thorac Oncol.2011; 6(7): 1179–1189.
44.
LiQ.Q., ChenZ.Q., CaoX.X.. Involvement of NF-κB/miR-448 regulatory feedback loop in chemotherapy-induced epithelialmesenchymal transition of breast cancer cells. Cell Death Differ.2011; 18(1): 16–25.
45.
LingB., WangG-X, LongG., QiuJ-H, HuZ-L. Tumor suppressor miR-22 suppresses lung cancer cell progression through posttranscriptional regulation of ErbB3. J Cancer Res Clin Oncol.2012; 138(8): 1355–1361.
46.
TakehaS., FujiyamaY., BambaT., SorsaT., NaguraH., OhtaniH.Stromal expression of MMP-9 and urokinase receptor is inversely associated with liver metastasis and with infiltrating growth in human colorectal cancer: a novel approach from immune/inflammatory aspect. Jpn J Cancer Res.1997; 88(1): 72–81.
47.
LeiL., HuangY., GongW.miR-205 promotes the growth, metastasis and chemoresistance of NSCLC cells by targeting PTEN. Oncol Rep.2013; 30(6): 2897–2902.
48.
LiuZ.L., WangH., LiuJ., WangZ.X.MicroRNA-21 (miR-21) expression promotes growth, metastasis, and chemo- or radioresistance in non-small cell lung cancer cells by targeting PTEN. Mol Cell Biochem.2013; 372(1-2): 35–45.
49.
Zöchbauer-MüllerS., FongK.M., VirmaniA.K., GeradtsJ., GazdarA.F., MinnaJ.D.Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res.2001; 61(1): 249–255.
50.
SoriaJ-C, LeeH-Y, LeeJ.I.. Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res.2002; 8(5): 1178–1184.
51.
ZhangJ.G., WangJ.J., ZhaoF., LiuQ., JiangK., YangG.H.MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). Clin Chim Acta.2010; 411(11-12): 846–852.
52.
BleauA.M., HambardzumyanD., OzawaT.. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell.2009; 4(3): 226–235.
53.
CarneroA., Blanco-AparicioC., RennerO., LinkW., LealJ.F.The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets.2008; 8(3): 187–198.
54.
ChenJ.S., WangQ., FuX.H.. Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: association with MMP-9. Hepatol Res.2009; 39(2): 177–186.
55.
FormosaA., MarkertE.K., LenaA.M.. MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c, miR-377, miR-381, miR-487b, miR-485-3p, miR-495 and miR-654-3p, mapped to the 14q32. 31 locus, regulate proliferation, apoptosis, migration and invasion in metastatic prostate cancer cells. Oncogene.2013; 33(44): 5173–5182.
56.
AdamsP.D., SellersW.R., SharmaS.K., WuA.D., NalinC.M., KaelinW.G.Jr.. Identification of a cyclin-cdk2 recognition motif present in substrates and p21-like cyclin-dependent kinase inhibitors. Mol Cell Biol.1996; 16(12): 6623–6633.
57.
WangH., ZhuL.J., YangY.C., WangZ.X., WangR.MiR-224 promotes the chemoresistance of human lung adenocarcinoma cells to cisplatin via regulating G1/S transition and apoptosis by targeting p21 (WAF1/CIP1). Br J Cancer.2014; 111(2): 339–354.
58.
YuS.Y., LiaoC.H., ChienM.H., TsaiT.Y., LinJ.K., WengM.S.Induction of p21 (Waf1/Cip1) by garcinol via downregulation of p38-MAPK signaling in p53-independent H1299 lung cancer. J Agric Food Chem.2014; 62(9): 2085–2095.
